antibioticsАнтибиотики и ХимиотерапияAntibiot Khimioter = Antibiotics and Chemotherapy0235-2990ООО «Издательство ОКИ»antibiotics-208Research ArticleОБЗОРЫREVIEWSТигециклингантимикробное действие, химиотерапевтическая эффективность и побочные реакцииTigecycline: Antimicrobial Action, Chemotherapeutic Efficacy and Adverse ReactionsНикитинА. В.NikitinA. V.noemail@neicon.ruжурнал «Антибиотики и химиотерапия»Russian Federation200913052020541-26366Copyright © ООО «Издательство ОКИ», 20202020ООО «Издательство ОКИ»ООО «Издательство ОКИ»https://www.antibiotics-chemotherapy.ru/jour/about/submissions#copyrightNoticehttps://www.antibiotics-chemotherapy.ru/jour/article/view/208Referenceshttp://clinicaltrials.gov/ct2/searchhttp://clinicaltrials.gov/ct2/searchOlson M.W., Ruzin A., Feyfant E., Rush T.S. et al. Functional biophysical and structural bases for antibacterial activity of tigecycline. Antimicrob Agent Chemother 2006; 50: 6: 2156-2166.Olson M.W., Ruzin A., Feyfant E., Rush T.S. et al. Functional biophysical and structural bases for antibacterial activity of tigecycline. Antimicrob Agent Chemother 2006; 50: 6: 2156-2166.Slover C.M., Rodvold K.A., Danziger L.H. Tigecycline:a novel broad-spectrum antimicrobial. Ann pharmacother 2007; 41: 6: 965-972.Slover C.M., Rodvold K.A., Danziger L.H. Tigecycline:a novel broad-spectrum antimicrobial. Ann pharmacother 2007; 41: 6: 965-972.Fernandes-Roblas R., Martin-de-Hijas N.Z., Fernandes-Martinez A.T., Garcia-Almeida D. et al. In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria. Antimicrob Agent Chemother 2008; 52: 11: 4184-4186.Fernandes-Roblas R., Martin-de-Hijas N.Z., Fernandes-Martinez A.T., Garcia-Almeida D. et al. In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria. Antimicrob Agent Chemother 2008; 52: 11: 4184-4186.Keeny D., Ruzin A., McAleese F., Murphy E. et al. MarA-mediated overexpression of the AcrAb efflux pump results in decreased susceptibility to tigecycline in Echerichia coli. Antimicrob Chemother 2008; 61: 1: 46-53.Keeny D., Ruzin A., McAleese F., Murphy E. et al. MarA-mediated overexpression of the AcrAb efflux pump results in decreased susceptibility to tigecycline in Echerichia coli. Antimicrob Chemother 2008; 61: 1: 46-53.Kelesidis T., Karageorgopoulos D.E., Kelesidis I., Falagas M.E. Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. Ibid; 62: 5: 895-904.Kelesidis T., Karageorgopoulos D.E., Kelesidis I., Falagas M.E. Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. Ibid; 62: 5: 895-904.Pankuch G.A., Appelbaum P.C. Postantibiotic effect of tigecycline against 14 Gram-positive organisms. Antimicrob Agent Chemother 2009; 53: 2: 782-784.Pankuch G.A., Appelbaum P.C. Postantibiotic effect of tigecycline against 14 Gram-positive organisms. Antimicrob Agent Chemother 2009; 53: 2: 782-784.Castanheira M., Sader H.S., Despande L.M., Fritsche T.R. et al. Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase and metallo-β-lactamase-producing Enterobacteriaceae: report from the SENTRY antimicrobial surveillance program. Ibid; 2008; 52: 2: 570-573.Castanheira M., Sader H.S., Despande L.M., Fritsche T.R. et al. Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase and metallo-β-lactamase-producing Enterobacteriaceae: report from the SENTRY antimicrobial surveillance program. Ibid; 2008; 52: 2: 570-573.Postier R.G., Green S.L., Klein S.R., Ellis-Grosse E.J. et al. Tigecycline 200 Study Group results of a multicenter randomized open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin structure infections in hospitalized patients. Clin Ther 2004; 26: 704-714.Postier R.G., Green S.L., Klein S.R., Ellis-Grosse E.J. et al. Tigecycline 200 Study Group results of a multicenter randomized open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin structure infections in hospitalized patients. Clin Ther 2004; 26: 704-714.Package insert.Tygacil (tigecycline) for injection. Philadelphia, PA. Wyeth Pharmaceuticals. June 2005.Package insert.Tygacil (tigecycline) for injection. Philadelphia, PA. Wyeth Pharmaceuticals. June 2005.Kaushik V., Beduya D., Kalampokis I., Kohlhoff S. et al. Tetracyclines tigecycline and doxycycline inhibit LPS-induced nitric oxide production by RAW 264.7 murine macrophages. J Immunol 2007, 178: 101. 3.Kaushik V., Beduya D., Kalampokis I., Kohlhoff S. et al. Tetracyclines tigecycline and doxycycline inhibit LPS-induced nitric oxide production by RAW 264.7 murine macrophages. J Immunol 2007, 178: 101. 3.Salvatore C.M., Techasaensiri C., Tagliabue C., Katz K. et al. Tigecycline therapy significantly reduces inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia. Antimicrob Agents Chemother doi:10.1128/AAC.00979-08.Salvatore C.M., Techasaensiri C., Tagliabue C., Katz K. et al. Tigecycline therapy significantly reduces inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia. Antimicrob Agents Chemother doi:10.1128/AAC.00979-08.Swoboda S., Ober M., Hainer Ch., Lichtenstern Ch. et al. Tigecycline for the treatment of patients with severe sepsis or septic shock: a drug use evaluation in a surgical intensive care unit. Antimicrob Chemother 2008; 61: 3: 729-733; doi:10.1093/jac/dkm541Swoboda S., Ober M., Hainer Ch., Lichtenstern Ch. et al. Tigecycline for the treatment of patients with severe sepsis or septic shock: a drug use evaluation in a surgical intensive care unit. Antimicrob Chemother 2008; 61: 3: 729-733; doi:10.1093/jac/dkm541Ellis-Grosse E.J., Babinchak T., Dartois N., Rose G. et al. TigecyclineEllis-Grosse E.J., Babinchak T., Dartois N., Rose G. et al. TigecyclinecSSSI Study Group; Tigecycline 305 cSSSI Study Group. The efficacy and safety of tigecycline in the treatment of skin and skinstructure in fections:results of 2 double-blind phase 3 comparison studies with vancomycin - aztreonam. Clin Infect Dis 2005; 41: Suppl 5: 341-353.cSSSI Study Group; Tigecycline 305 cSSSI Study Group. The efficacy and safety of tigecycline in the treatment of skin and skinstructure in fections:results of 2 double-blind phase 3 comparison studies with vancomycin - aztreonam. Clin Infect Dis 2005; 41: Suppl 5: 341-353.Babinchak T., Ellis-Grosse E.J., Dartois N., Rose G. et al. TigecyclineBabinchak T., Ellis-Grosse E.J., Dartois N., Rose G. et al. TigecyclineStudy Group; Tigecycline 306 Study Group. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections:analysis of pooled clinical trial data. Ibid; 354-367.Study Group; Tigecycline 306 Study Group. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections:analysis of pooled clinical trial data. Ibid; 354-367.
The authors declare that there are no conflicts of interest present.